Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Sponsors
Tata Memorial Centre
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with FIGO 2018 stage IB-IVA cervical cancer with squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma histological subtype. 2. Planned for treatment with definitive chemo-radiation and brachytherapy. (X-ray, CT, CT-Ultrasound or MRI based)
Exclusion criteria
Exclusion criteria: 1. Neuroendocrine cancer of the cervix or other rare histology subtypes. 2. Patients with metastatic cervix cancer and not planned for radical doses of pelvic RT/brachytherapy may be excluded. 3. Patients undergoing postoperative RT or RT for recurrent disease should be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recording and reporting the prevalent practices of cervical cancer brachytherapy in the management of cervical cancer in FARO member countries and report outcomes in reference to techniques utilised.Timepoint: for the duration of 3 years | — |
Secondary
| Measure | Time frame |
|---|---|
| To record and report techniques utilised for external radiation and report outcomes in reference to EBRT techniques and prescription.Timepoint: For the entire duration of the three year study;To report utilisation rates of concurrent chemotherapy and report outcomes in reference to cumulative cisplatin dose delivered.Timepoint: For the entire duration of the three year study;To record and report on prevalent brachytherapy fractionation regimes across participating sites.Timepoint: For the entire duration of the three year study;To record and report on overall treatment times for the management of cervical cancer.Timepoint: For the entire duration of the three year study;To report 2-year local control, regional control and disease-free survival in reference to primary and nodal dose and chemotherapy dose in different subcohorts of cervical cancer.Timepoint: 2 Years from treatment completion date;To report 2-year gastrointestinal, genitourinary, hematological and vaginal adverse events with use of radiation and brachytherapy using CTCAE version 5.0Timepoint: 2 Years from treatment completion date | — |
Countries
India, Japan, Thailand
Contacts
Public ContactDr Supriya Chopra
Tata Memorial Centre
Outcome results
None listed